Henry Meds vs Alan Meds: Models, Eligibility, and Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, our neutral guide to GLP-1 telehealth programs and the genetics that underlie them. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Henry Meds or Alan Meds and receives no affiliate compensation from either.

Full head-to-head: PlexusDx vs Henry Meds →

Henry Meds and Alan Meds are two entries in a crowded telehealth GLP-1 field. This head-to-head keeps the framing practical: how each brand is structured, where their models overlap, what separates them at the margins, and the one factor neither addresses. Current as of April 2026.

Two programs, one delivery model

Both Henry Meds and Alan Meds run on the telehealth-plus-compounding template: a virtual clinical evaluation, a provider-issued prescription, and fulfillment through either a retail pharmacy for branded GLP-1s or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. On the surface they are close cousins, which is exactly why the differences that remain matter.

Eligibility and clinical gate

With each brand, access begins at an intake form and a clinician's review rather than a shelf you can buy from. Approval hinges on the medical information you submit, and a prescription follows only if you qualify. Differences tend to appear in provider type (physician versus NP or PA) and how tightly each program structures follow-up. Confirm each brand's clinical model on its own site. Because approval is clinical rather than commercial, neither brand can promise access before a provider signs off, and that gate holds no matter which name is on the website.

Where the two diverge

The practical distinctions are the dispensing pathway (branded versus compounded), the subscription structure, and the specific medication menu each offers. Alan Meds's current program details and Henry Meds's should both be read from their own pages, since offerings in this category are revised frequently and a difference true today may not hold next quarter.

Pricing without stale numbers

Rather than quote figures that age quickly, treat pricing as a range: across the telehealth GLP-1 market as of April 2026, all-in monthly totals commonly fall between roughly $200 and $700 or more, covering program fees, medication, and compounded dispensing where it applies. Both Alan Meds and Henry Meds publish their own current pricing; verify each directly before deciding.

The pharmacology is identical; the biology is not

Neither brand changes the underlying compound class: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide, backed by STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024). What does differ from person to person is genetic. Variants in FTO, GLP1R, MC4R, and TCF7L2 map the metabolic baseline any GLP-1 acts upon — pathway-level context, not a response prediction, that neither Henry Meds nor Alan Meds captures.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection at $189/month, Tirzepatide Injection at $289/month, plus Semaglutide Oral and Tirzepatide Oral. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights and does not predict response to any specific medication.

Not affiliated: PlexusDx is independent of both Henry Meds and Alan Meds and has no commercial relationship with the companies reviewed here.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Henry Meds or Alan Meds and has no commercial relationship with the companies reviewed. PlexusDx offers its own Weight Management Protocols, so this piece compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Compare the approach: see the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions

Is Henry Meds or Alan Meds the better choice?

Neither is objectively better. Both run on the same telehealth-plus-compounding model, so fit comes down to the specific medication menu, subscription terms, and provider structure that suit you. Review each brand's own current details, and weigh cost and clinical model rather than looking for a single winner.

Do Henry Meds and Alan Meds prescribe the same drugs?

Both can prescribe GLP-1 receptor agonists through telehealth, but their exact menus and dispensing pathways differ. One may lean more on compounded formulations, the other on branded products, and formats vary. The underlying pharmacology depends on the compound itself, not the platform delivering it.

Does either program work with insurance?

Cash-pay compounded GLP-1 telehealth is generally not billed through insurance, though coverage varies by plan and product. Check each brand's current policy and your own benefits directly. Compounded medications in particular are frequently excluded from coverage, so confirm before assuming any reimbursement.

How does genetics factor into either program?

Neither Henry Meds nor Alan Meds evaluates your genetic baseline. The Precision Peptide Genetic Test analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that describe your metabolic starting point. It does not predict response to any compound but provides context that applies across every GLP-1 program.

More in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.